Recon Supply Named Exclusive U.S. Distributor of ReShape’s STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service MembersIRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon Supply. Through this new strategic partnership, Recon Supply will distribute ReShape’s cutti ...

IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6 million before deducting placement agent fees and other offering expenses. The offering is expected to close on ...

IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively. The EU MDR, which replaced the Medical Device ...

Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards CompletionIRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and Subsequent Highlights May 2025: Effected a 1-for-25 reverse stock split of the comp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other ...

文章核心观点 公司董事会宣布进行1比25的反向股票分割，将于2025年5月9日交易开始时生效 [1] 反向股票分割详情 - 反向股票分割生效时间为2025年5月9日交易开始时，届时每25股已发行和流通的普通股及等价物将转换为1股普通股 [1] - 反向股票分割后，公司未行使的认股权证、股票期权和可转换优先股的行权或转换时可发行的普通股数量及每股行权或转换价格将按条款进行比例调整 [1] - 反向股票分割产生的任何零碎普通股将向上取整为最接近的整数股，公司公司章程下的普通股和优先股授权股数不会因反向股票分割而减少 [1] - 反向股票分割已在2025年4月1日的公司特别股东大会上获得股东批准 [2] - 公司股东将收到过户代理Equiniti Trust Company, LLC关于用现有股票证书换取新证书或账面股票的程序指示 [2] - 反向股票分割后公司普通股的新CUSIP编号为76090R408 [2] 公司简介 - 公司是美国领先的减肥和代谢健康解决方案公司，提供管理和治疗肥胖及代谢疾病的产品和服务组合 [3] - 公司拥有FDA批准的Lap - Band系统，可微创长期治疗肥胖，是胃旁路或袖状胃切除术等更具侵入性手术的替代方案 [3] - 公司的研究性糖尿病阻断刺激神经调节（DBSN™）系统利用专有迷走神经阻断和刺激技术平台治疗2型糖尿病和代谢紊乱 [3] - 公司的Obalon气球技术是一种非手术、可吞咽、充气的胃内气球，旨在实现持久减肥 [3] 联系方式 - 公司投资者联系人是总裁兼首席执行官Paul F. Hickey，电话949 - 276 - 7223，邮箱ir@ReShapeLifesci.com [4] - 投资者关系联系人是Rx Communications Group的Michael Miller，电话917 - 633 - 6086，邮箱mmiller@rxir.com [4]

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present pre-clinical data on its proprietary Diabetes Neuromodulation device ...

Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric DeviceIRVINE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, “Intragastric Device.” When issued, the patent will cover claims ...

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allow ...

ReShape Lifesciences (RSLS) Q4 2024 Earnings Call April 10, 2025 10:09 PM ET Company Participants Michael Miller - Managing DirectorPaul Hickey - CEO, President & DirectorTom Stankovich - Chief Financial Officer Operator Good afternoon, and thank you for joining the Lifesciences Earnings Highlights and Strategic Update Conference Call. I would now like to turn the call over to Michael Miller from Rx Communications. Michael Miller Good afternoon, and thank you for joining the ReShape Lifesciences Earnings Hi ...